Phosphatidylserine targeting for diagnosis and treatment of human diseases.
Cells are able to execute apoptosis by activating series of specific biochemical reactions. One of the most prominent characteristics of cell death is the externalization of phosphatidylserine (PS), which in healthy cells resides predominantly in the inner leaflet of the plasma membrane. These features have made PS-externalization a well-explored phenomenon to image cell death for diagnostic purposes. In addition, it was demonstrated that under certain conditions viable cells express PS at their surface such as endothelial cells of tumor blood vessels, stressed tumor cells and hypoxic cardiomyocytes. Hence, PS has become a potential target for therapeutic strategies aiming at Targeted Drug Delivery. In this review we highlight the biomarker PS and various PS-binding compounds that have been employed to target PS for diagnostic purposes. We emphasize the 35 kD human protein annexin A5, that has been developed as a Molecular Imaging agent to measure cell death in vitro, and non-invasively in vivo in animal models and in patients with cardiovascular diseases and cancer. Recently focus has shifted from diagnostic towards therapeutic applications employing annexin A5 in strategies to deliver drugs to cells that express PS at their surface.
Schutters
Kristof
K
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands. k.schutters@maastrichtuniversity.nl
Reutelingsperger
Chris
C
D000818:Animals; D017304:Annexin A5 / Q000378:metabolism; D003933:Diagnosis; D003952:Diagnostic Imaging; D004358:Drug Therapy; D006801:Humans; D010718:Phosphatidylserines / Q000378:metabolism*; D011485:Protein Binding; D050863:Synaptotagmin I / Q000378:metabolism
D017304:Annexin A5; D010718:Phosphatidylserines; D050863:Synaptotagmin I